CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it will host a live webcast to present and discuss the newly disclosed, late-breaking 48-week Phase 3 clinical data in China for...

People

6 Energy-Saving Tips

Bahamas Ministry of Tourism, Investments, and Aviation announces inaugural Bahamas Women...

Strut Health Under Review: Most Trusted Personalized Weight Loss, Sexual Health,...

Wood Bio-Products Market to Reach USD 607.59 Billion by 2032 |...

Vietnam’s first-ever vegan wedding between a music icon and an entrepreneur...

Glycolic Acid Market to Reach USD 648.92 million by 2032 |...

JASIWAY Sets New Standard for Whole-Home Furniture with Functional Elegance and...

Perfect Gift for Pregnant Moms: Momcozy Maternova Belly Band

Hydrolysed Collagen Market Growth Outlook, Unlocking Potential in Nutraceutical and Cosmetic...

K-Beauty Products Market – Global Industry Analysis and Forecasts to 2032:...

Japan Hotel Market to Reach US$ 26.85 Billion by 2033, Driven...

Featured

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept...

6 Energy-Saving Tips

Saudia Unveils SV Lifestyle Brand at Riyadh Fashion Week

All Star Digital and Dart Co Launch One Hitters: Exclusive Partnership...

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept...